Facial dermatoses and use of protective mask during Covid-19 pandemic: A clinical and psychological evaluation in patients affected by moderate-severe atopic dermatitis under treatment with dupilumab코비드-19 대유행 중 안면 피부병 및 보호 마스크 사용: 두필루맙 치료 중 중등도 아토피 피부염에 걸린 환자의 임상 및 심리학적 평가Article Published on 2022-07-012022-09-12 Journal: Dermatologic therapy [Category] COVID19(2023년), MERS, SARS, 진단, [키워드] affected allergic disease Analysis atopic atopic dermatitis calculated contribute COVID-19 Diseases distress Dupilumab Efficacy ENhance evaluate evaluated Evidence exacerbate face Face mask facial facial dermatoses. greater HADS incidence include Inflammatory Italy mandatory Mask Masks Mental moderate-severe Modification Novara pandemic Patient patients Prevalence Protective protective effect Psychological psychological Impact psychological score recorded reducing reduction in severity significantly significantly lower statistically significant difference subject therapy treated Treatment two group two groups [DOI] 10.1111/dth.15573 PMC 바로가기 [Article Type] Article
Dupilumab therapy in atopic dermatitis is safe during COVID-19 infection era: A systematic review and meta-analysis of 1611 patients코로나19 감염시대 아토피 피부염에 두필루맙 치료는 안전하다: 1611명의 환자를 대상으로 한 체계적 고찰 및 메타분석Review Published on 2022-06-012022-09-12 Journal: Dermatologic therapy [Category] 진단, [키워드] 95% confidence interval Academy appraisal atopic atopic dermatitis cough COVID-19 COVID-19 infection COVID-19 symptom database died disease Dupilumab Dyspnea eligible Europe evaluate Evidence fatigue Fever FIVE gastrointestinal symptoms Google Scholar Gray hazard Hospitalized Joanna Briggs Institute library literature loss of taste management Medicine Meta-analysis New York outcome pandemic Patient patients patients with COVID-19 Prevalence prevalence of COVID-19 reported risk Safe searched Symptom System systematic review therapy treated was performed Web of Science [DOI] 10.1111/dth.15476 PMC 바로가기 [Article Type] Review
Patients Withdrawing Dupilumab Monotherapy for COVID-19-Related Reasons Showed Similar Disease Course Compared With Patients Continuing Dupilumab TherapyCOVID-19 관련 이유로 두필루맙 단독 요법을 중단한 환자는 두필루맙 요법을 계속하는 환자와 유사한 질병 경과를 보였다Article Published on 2022-05-012022-09-12 Journal: Dermatitis : contact, atopic, occupational, drug [Category] MERS, 진단, [키워드] Dupilumab reason Showed [DOI] 10.1097/DER.0000000000000814 PMC 바로가기 [Article Type] Article
Infections in children and adolescents treated with dupilumab in pediatric clinical trials for atopic dermatitis—A pooled analysis of trial dataOriginal Article Published on 2022-01-262024-09-04 Journal: Pediatric dermatology [Category] 대상포진, [키워드] atopic dermatitis Dupilumab herpetic skin infections IL‐13 IL‐4 skin infections systemic infections [DOI] 10.1111/pde.14909 PMC 바로가기 [Article Type] Original Article
COVID-19 Symptoms Are Attenuated in Moderate-to-Severe Atopic Dermatitis Patients Treated with DupilumabCOVID-19 증상은 Dupilumab으로 치료받은 중등도에서 중증 아토피 피부염 환자에서 완화됩니다Article Published on 2022-01-012022-09-12 Journal: The journal of allergy and clinical immunology. In [Category] MERS, 진단, [키워드] adjusted Anti-viral assigned Asymptomatic atopic dermatitis biologics Control covariate COVID-19 COVID-19 symptom COVID-19 symptoms COVID-19-related symptom demographic Department dermatitis disease Dupilumab enrolled entire cohort immune response Immunity immunomodulatory medication incidence Inflammatory diseases less logistic regression models Medicine modulation Mount Sinai pandemic Patient protective effect reduced SARS-CoV-2 School score screened severe COVID-19 manifestation severity severity of COVID-19 subgroup of patient Symptom Th2 Th2. Treatment treatment groups viral infection [DOI] 10.1016/j.jaip.2021.10.050 PMC 바로가기 [Article Type] Article
Dupilumab in adolescents with moderate to severe atopic dermatitis: a 32-week real-world experience during the COVID-19 pandemic중등도에서 중증의 아토피 피부염을 가진 청소년의 Dupilumab: COVID-19 전염병 동안 32주간의 실제 경험Article Published on 2022-01-012022-09-12 Journal: Clinical and experimental dermatology [Category] MERS, 진단, [키워드] atopic COVID-19 pandemic Dupilumab moderate [DOI] 10.1111/ced.14862 PMC 바로가기 [Article Type] Article
Risk of COVID-19 and its complications in patients with atopic dermatitis undergoing dupilumab treatment—a population-based cohort study두필루맙 치료를 받는 아토피 피부염 환자의 코로나19 위험 및 합병증 - 인구 기반 코호트 연구Original Article Published on 2021-10-132022-09-12 Journal: Immunologic research [Category] COVID19(2023년), MERS, SARS, 진단, [키워드] 95% CI AD atopic dermatitis azathioprine biologics comparable Complication complications conducted coronavirus disease Corticosteroids COVID-19 COVID-19 complication COVID-19 complications Dupilumab elevated Hospitalization incidence of COVID-19 incidence rate increased risk Infection Mortality mycophenolate mycophenolate mofetil pandemic Patient patients treated phototherapy population-based cohort risk Safe SARS-COV-2 infection systemic corticosteroid treated [DOI] 10.1007/s12026-021-09234-z PMC 바로가기 [Article Type] Original Article
The Use of Biologics During the COVID-19 PandemicReview article Published on 2021-10-012022-10-05 Journal: Dermatologic Clinics [Category] 임상, [키워드] atopic dermatitis biologics COVID-19 Dupilumab hidradenitis suppurativa IL inhibitor psoriasis TNF-Inhibitor [DOI] 10.1016/j.det.2021.05.010 [Article Type] Review article
IL-13 is a driver of COVID-19 severityIL-13은 COVID-19 심각성의 동인입니다Research Article Published on 2021-08-092022-09-10 Journal: JCI Insight [Category] MERS, SARS, 유전자 메커니즘, [키워드] accumulation addition administration block blockade CD44 characteristic contribute COVID-19 COVID-19 severity cytokine Cytokines death disease severity downregulated gene Dupilumab dysregulation elevated Has1 highlighting Hyaluronan IL-13 IL-4 immune dysregulation immune system immunology implication independent Innate immunity less lung Lung disease Lungs mAb mechanical ventilation mechanism mediator mice Mortality mouse model neutralization open pathogenic Patient patient cohorts patients with COVID-19 plasma polysaccharide prevented pulmonary diseases Pulmonary pathology receptor reduced SARS-COV-2 infection SARS-CoV-2–infected mice severe COVID-19 severe disease Signaling Stage Th2 response the disease therapy Treatment understanding Viral Viral load was increased without affecting [DOI] 10.1172/jci.insight.150107 PMC 바로가기 [Article Type] Research Article
Advances in atopic dermatitisCME: Dermatology Published on 2021-05-012024-09-04 Journal: Clinical medicine (London, England) [Category] 대상포진, [키워드] atopic eczema dermatitis Dupilumab jak inhibitors [DOI] 10.7861/clinmed.2021-0280 PMC 바로가기 [Article Type] CME: Dermatology